drugset / Trial / NCT00979251
Oral Triple Combination Antiviral Drug Therapy for Treatment of Influenza A in Immunocompromised Subjects
RandomizedParallel-groupOpen-labelTreatment
Summary
This Phase 2, open label, randomized study will investigate the virologic benefit, clinical efficacy, safety, and tolerability of amantadine and ribavirin with oseltamivir (TCAD) versus oseltamivir monotherapy for the treatment of all strains of influenza A in immunocompromised adult and pediatric subjects.
Timeline
- Start
- 2009-09
- Primary completion
- 2010-05
- Completion
- 2011-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amantadine | Unknown | — | Oral |
| Subject | Ribavirin | Small molecule | — | Oral |
| Comparator | Oseltamivir | Small molecule | — | Oral |